Andrew Warren

Author:

Andrew Warren

ISBN #:

0195209419

Author:

Andrew Warren

ISBN #:

0540089486

Author:

Andrew Warren

ISBN #:

0471921149

Author:

Andrew Warren

ISBN #:

0471984981

Author:

Andrew Warren

ISBN #:

0713421045

US Patent:

20200245926, Aug 6, 2020

Filed:

Mar 15, 2019

Appl. No.:

16/355110

Inventors:

- Cambridge MA, US
Gabriel Kwong - Atlanta GA, US
Eric Huang - Lexington MA, US
Sirshendu Roopom Banerjee - Lexington MA, US
Andrew Warren - Cambridge MA, US
Sophie Cazanave - Cambridge MA, US

International Classification:

A61B 5/00
A61K 38/48
A61K 47/10
A61K 9/00
G01N 33/50
G01N 33/574
G01N 33/68

Abstract:

The present invention provides method for longitudinal monitoring of disease changes and/or drug response. At multiple time points, a composition is introduced into a body of a subject (the composition includes an activity sensor comprising a plurality of reporters liberated through enzymatic cleavage, which occurs in a tissue of the body when enzymes associated with known activity of a therapeutic intervention are present in the body) and reporters are detected to determine activity levels of disease-associated enzymes in the subject, which is correlated to changes in disease state and/or drug response. A report or therapeutic response profile may further be used to support a clinical trial and for longitudinal monitoring of disease progression or regression in a subject. A prospective or active clinical trial participant, or patient undergoing treatment, may be qualified, stratified or staged based on the determined activity levels.

US Patent:

20200246489, Aug 6, 2020

Filed:

Jan 30, 2020

Appl. No.:

16/777025

Inventors:

- Cambridge MA, US
Gabriel Kwong - Atlanta GA, US
Eric Huang - Lexington MA, US
Sirshendu Roopom Banerjee - Lexington MA, US
Andrew David Warren - Cambridge MA, US
Sophie Cazanave - Cambridge MA, US

International Classification:

A61K 49/00
C12Q 1/37
A61B 6/00

Abstract:

Methods of the present invention predict a physiological state of a subject. A composition comprising activity sensors is introduced into a body of a subject. The activity sensors comprise a plurality of reporters susceptible to cleavage when processed by the body during extracellular matrix remodeling. Cleavage may be indicative of enzymatic activity in the extracellular matrix. Signals detected by the activity sensors may be predictive of a physiological state. A sample is collected from the subject, and liberated reporters are detected in the sample. An onset of the physiological state of the subject, which may be a disease characterized by inflammation or atrophy, may be diagnosed based on the liberated reporters detected.

US Patent:

20200249229, Aug 6, 2020

Filed:

Jan 30, 2020

Appl. No.:

16/776991

Inventors:

- Cambridge MA, US
Gabriel Kwong - Atlanta GA, US
Eric Huang - Lexington MA, US
Sirshendu Roopom Banerjee - Lexington MA, US
Andrew David Warren - Cambridge MA, US
Sophie Cazanave - Cambridge MA, US

International Classification:

G01N 33/569
G01N 33/543

Abstract:

The invention provides methods and compositions that use a process in the body to deliver an active form of the activity sensor to a target site within the body. The activity sensors, which release detectable reporters when acted on by certain enzymes within the body, are provided as pro-analytes. Processes within the body deliver the activity sensors in active form to a target site of interest. For example, enzymes or a chemical environment within the body may cleave blocking groups from the activity sensors, or the body's tissues and organs may collect the activity sensors at the target site based on size or composition of the activity sensors.

US Patent:

20190376113, Dec 12, 2019

Filed:

Mar 15, 2019

Appl. No.:

16/355178

Inventors:

- Cambridge MA, US
Gabriel Kwong - Atlanta GA, US
Eric Huang - Lexington MA, US
Sirshendu Roopom Banerjee - Lexington MA, US
Andrew Warren - Cambridge MA, US
Sophie Cazanave - Cambridge MA, US

International Classification:

C12Q 1/37

Abstract:

A nanoparticle activity sensor containing a reporter and at least one tuning domain that modifies a distribution or residence time of the activity sensor when administered to a patient. When administered to the patient, the activity sensor enters cells or tissue where it is cleaved by enzymes specific to a physiological state such as a disease to release a detectable analyte. The tuning domains include molecular structures that modulate distribution or decay by protecting the particle from premature cleavage and indiscriminate hydrolysis, shielding the particle from immune detection and clearance, or by targeting the particle to specific tissue, bodily fluids, or cell types.

US Patent:

20190376114, Dec 12, 2019

Filed:

Mar 15, 2019

Appl. No.:

16/355225

Inventors:

- Cambridge MA, US
Gabriel Kwong - Atlanta GA, US
Eric Huang - Lexington MA, US
Sirshendu Roopom Banerjee - Lexington MA, US
Andrew Warren - Cambridge MA, US
Sophie Cazanave - Cambridge MA, US

International Classification:

C12Q 1/37

Abstract:

Methods and compositions for screening or diagnosis of liver disease are provided. The results may also indicate course and efficacy of treatment. The composition includes an activity sensor and a reporter releasably attached to the activity sensor. The method includes detecting the presence and/or amount of a reporter. The reporter is released from an activity sensor in the presence of diseased liver tissue but remains attached to the activity sensor in healthy tissue. The presence and/or amount of the reporter are used to characterize the liver disease. The liver disease may be nonalcoholic steatohepatitis (NASH) and results may further indicate staging of NASH.

US Patent:

20190376115, Dec 12, 2019

Filed:

Jun 7, 2019

Appl. No.:

16/434785

Inventors:

- Cambridge MA, US
Gabriel Kwong - Atlanta GA, US
Eric Huang - Lexington MA, US
Sirshendu Roopom Banerjee - Lexington MA, US
Andrew Warren - Cambridge MA, US
Sophie Cazanave - Cambridge MA, US

International Classification:

C12Q 1/37
C12Q 1/6886
G16B 40/00
G16B 50/00

Abstract:

Methods of the disclosure provide an analytical pipeline for mapping activity in a disease-specific manner. Any of a variety of diseases or medical conditions may be mapped using the analytical pipeline. In preferred embodiments, the pipeline uses expression data (e.g., from RNA-Seq) to identify proteases that are active in disease tissue and subject to differential expression relative to normal tissue. A machine learning classifier selects a subset of the proteases that identify the disease with a threshold sensitivity and specificity, in which the subset is small enough that a corresponding set of protease substrates may be assembled into a nanoparticle activity sensor that, when administered to a patient, are cleaved in the presence of disease tissue to release detectable analytes signifying presence of the disease.